LLY — Recent News Coverage
All news mentioning LLY in ESEN's AI-graded feed
News stories with LLY as an affected ticker. Each article is graded by ESEN AI for impact level and direction (up/down/flat) on LLY. See /coverage/LLY for the 30-day aggregate.
INVESTING.COM
·
2026-06-18
NEUTRAL
BULLISH
CORR0.58
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound
$LLY
$HUM
$DXCM
$JNJ
◈ ESEN AI
Eli Lilly (LLY), Humana (HUM), and DexCom (DXCM) are emerging as key drivers of a healthcare sector rebound, signaling renewed investor confidence in pharmaceutical innovation, managed care platforms, and continuous glu…
INSIDERMONKEY.COM
·
2026-06-18
NEUTRAL
BULLISH
CORR0.42
What’s Happening at Eli Lilly and Company (LLY)’s Pipeline? Early Signals Emerge
$LLY
◈ ESEN AI
Eli Lilly (LLY) disclosed Phase 1 trial data for AJX-101, an experimental asset in its clinical pipeline. The company has positioned itself among peers with exceptional forward earnings visibility, with consensus models…
FINANCE.YAHOO.COM
·
2026-06-17
NEUTRAL
BULLISH
CORR0.52
Jim Cramer on Eli Lilly: “I Want You to Stay in the Stock”
$LLY
◈ ESEN AI
Eli Lilly (LLY) received a positive endorsement from CNBC's Jim Cramer on Mad Money, reinforcing conviction among retail and institutional viewers tracking the pharmaceutical sector. The analyst's directional stance—urg…
FINANCE.YAHOO.COM
·
2026-06-17
NEUTRAL
BULLISH
CORR0.72
10 Best Growth Stocks to Buy According to Billionaire Ray Dalio’s Bridgewater Associates
$META
$NVDA
$MSFT
$LLY
$MRVL
◈ ESEN AI
Bridgewater Associates' curated growth stock list reflects Ray Dalio's conviction that earnings momentum remains the primary driver of equity valuations despite macroeconomic headwinds. The portfolio tilts heavily towar…
CNBC.COM
·
2026-06-16
NEUTRAL
BULLISH
CORR0.58
Lilly opens its checkbook again, and an insider buy at Broadcom captures our attention
$LLY
$AVGO
◈ ESEN AI
Eli Lilly (LLY) continues its aggressive capital deployment strategy, signaling management confidence in future cash generation and M&A/R&D pipeline expansion. This spending pattern reflects pharmaceutical sector optimi…
MANILATIMES.NET
·
2026-06-16
NEUTRAL
NEUTRAL
CORR0.25
Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight
$INCY
$LLY
$PFE
◈ ESEN AI
The glioblastoma therapeutic pipeline continues to expand with over 220 drug candidates across multiple clinical development stages. This represents a fragmented competitive landscape where numerous biotechnology and ph…
SEEKINGALPHA
·
2026-06-16
NEUTRAL
NEUTRAL
CORR0.35
Lilly acquires pain therapy developer 4E Therapeutics
$LLY
◈ ESEN AI
Eli Lilly (LLY) has acquired 4E Therapeutics, a clinical-stage developer focused on pain management therapies. This transaction represents a strategic portfolio expansion within the pharmaceutical giant's oncology and p…
ECONOMICTIMES.INDIATIMES.COM
·
2026-06-16
NEUTRAL
BULLISH
CORR0.15
Kiran Mazumdar-Shaw eyes crown of world’s top insulin supplier for Biocon
$NVO
$LLY
◈ ESEN AI
Biocon's stated ambition to capture the world's largest insulin market share within five years signals a structural supply-side shift in global pharmaceuticals. The Indian drugmaker's competitive positioning exploits a …
FINANCE.YAHOO.COM
·
2026-06-13
LOW
BULLISH
CORR0.42
Jim Cramer Wasn’t Selling Eli Lilly (LLY)
$LLY
◈ ESEN AI
Eli Lilly (LLY) continues to garner favorable commentary from prominent market personalities, reinforcing its positioning within the healthcare sector. The stock has maintained analyst and media attention throughout 202…
INSIDERMONKEY.COM
·
2026-06-13
NEUTRAL
BULLISH
CORR0.72
10 Most Profitable Blue Chip Stocks to Buy According to Hedge Funds
$LLY
$JPM
◈ ESEN AI
Hedge fund positioning in blue-chip equities reflects confidence in earnings momentum heading into mid-2026. With S&P 500 companies tracking their strongest quarterly earnings growth through Q1 reporting season, institu…
FINANCE.YAHOO.COM
·
2026-06-12
NEUTRAL
NEUTRAL
CORR0.35
Eli Lilly (LLY) Moves to Enforce 340B Claims Data Reporting Compliance
$LLY
◈ ESEN AI
Eli Lilly (LLY) is enforcing compliance with 340B claims data reporting requirements by threatening to suspend discounted drug pricing access for non-compliant hospital partners. The 340B program, a federal initiative d…
RTTNEWS.COM
·
2026-06-12
HIGH
BULLISH
CORR0.72
Weekly Buzz: GH, LLY Gain FDA Nod; TEVA, GSK, Lead M&A Wave; ZEAL, LLY Post Strong Data
$LLY
$TEVA
$GSK
$ZEAL
◈ ESEN AI
LLY, TEVA, GSK, and ZEAL are driving a significant biotech rally this week, anchored by multiple FDA and regulatory approvals across oncology, dermatology, autoimmune, and rare disease indications. The breadth of approv…
EXPLORE OTHER FILTERS